![Figure 5: TAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling.](https://www.oncotarget.net/wp-content/uploads/2024/07/Screen-Shot-2024-07-08-at-4.55.44-PM-300x181.png)
Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers
July 8, 2024
In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.”BUFFALO, NY- July 8, 2024 – A new research paper... read more